Laparoscopy/robotics studies explore the limits of minimally invasive surgery
Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
This article is part of the State of Urology 2014
Dr. WolfUrologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
“Urologists continue to struggle to find the right place for surgical robots in our practice,” said J. Stuart Wolf, Jr., MD, professor of urology at the University of Michigan, Ann Arbor. “Additionally, we continue to explore novel concepts to make our procedures more effective, safer, or easier.”
Here are the abstracts Dr. Wolf says to watch for this year:
PD13-02: Long Term Renal Functional Outcomes of Minimally Invasive Partial Nephrectomy (MIPN) for Renal Cell Carcinoma
Anudeep Mukkamala
PD13-09: Development and Initial Porcine and Cadaveric Experience with Three-Dimensional Printing of Endoscopic and Laparoscopic Equipment
Michael del Junco
MP37-06: Multiparametric Magnetic Resonance Imaging and MRI/Ultrasound Fusion-Guided Biopsy Stratify Patients at Risk for Extracapsular Extension at Radical Prostatectomy
Dima Raskolnikov
MP37-07: Comparative effectiveness of robotic-assisted versus open radical prostatectomy cancer control outcomes
Ioana Popa
MP37-13: Use of the Robotic Surgical Platform for Radical Nephrectomy: A National Comparison of Utilization and Complications for Open, Laparoscopic, and Robotic Approaches
Aaron Weinberg
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Dr. Richard Matulewicz discusses smoking cessation counseling and treatment among urologists
March 31st 2021“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
